LABU250103P93000
- 0.21
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
AbbVie Analyst Ratings
Express News | Moderna and Novavax Surge Over 5% and 6% Respectively on CDC Report of Rising Respiratory Illness
Nvidia, Palantir, Ionq, Novavax, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today
U.S. stock market close: Inflation concerns lead to a decline in all indexes, NVIDIA fell 6% after reaching a new high.
① The Nasdaq China Golden Dragon Index fell by 0.2%, with China Concept Stocks showing mixed results; ② NVIDIA launched its personal computing product Project DIGITS; ③ XPENG Huaitian: Flying cars will be mass-produced and delivered in 2026; ④ Vaccine stocks soared, with Moderna rising nearly 12% and Novavax increasing by nearly 11%.
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Stocks Sink As Bond Yields Soar, Nvidia Eyes Worst Day In 4 Months, Bitcoin Tumbles To $97,000: What's Driving Markets Tuesday?
Looking Into Gilead Sciences's Recent Short Interest
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
UniFirst, Getty Images, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Spotlight on Moderna: Analyzing the Surge in Options Activity
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Bird Flu Claims First U.S. Life in Louisiana
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06